ClinicalTrials.gg
RecruitingNCT05208762Updated Jul 22, 2026

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

A Phase 1 interventional study of PF-08046054 and pembrolizumab in Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck and Esophageal Squamous Cell Carcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Recruiting at 62 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
714
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Planned enrollment
11th of 136
714 · median 79
Started
2022
with 6 others
Phase 1
56 of 158
6 open now
Primary completion
2028-01
later than 10 of 25 live
Registered
120th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 11th largest by planned enrollment of the 136 interventional ones that give a count, is one of 7 that started in 2022, is one of 56 in phase 1, reaches primary completion later than 10 of the 25 other live ones, and was the 120th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Squamous Cell Carcinoma of the Head and Neck
  • Esophageal Squamous Cell Carcinoma
  • Triple Negative Breast Neoplasms
  • Gastric Cancer
  • Endometrial Cancer
  • Pancreatic Adenocarcinoma
  • Hepatocellular Carcinoma

Keywords

  • Non-small cell lung cancer
  • NSCLC
  • Head and neck squamous cell carcinoma
  • HNSCC
  • Triple Negative Breast Cancer
  • TNBC
  • Gastric cancer
  • Seattle Genetics
  • HCC
  • PDAC
  • Esophageal
  • Pfizer
  • Endometrial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parts A and B:

    • Participants must have one of the following - or cytologically-confirmed or unresectable solid tumor types

      • Non-small cell lung cancer (NSCLC)
      • Head and neck squamous cell carcinoma (HNSCC) (except nasopharyngeal cancer)
      • Esophageal squamous cell carcinoma (SCC)
      • Triple negative breast cancer (TNBC)
    • Participants must have disease that is , that has progressed on approved therapies, be intolerant to or refused such therapies, or such and therapies are and in the judgement of the investigator, should have no appropriate SoC therapeutic option
    • Participants must have expression based on historical testing
  • Part C:

    • Participants must have disease that is relapsed or refractory or be intolerant to SoC therapies and must have one of the following tumor types

      • HNSCC

        • Participants with HNSCC must have histologically or cytologically-confirmed HNSCC
      • NSCLC

        • Participants must have histologically or cytologically-confirmed NSCLC. Participants with SCC and non--SCC histology are eligible. Note: Participants with a neuroendocrine component or histology are not eligible.
      • Esophageal SCC
      • Pancreatic cancer
      • Hepatocellular carcinoma
      • TNBC
      • Gastric cancer
      • Endometrial cancer
    • Participants must have been previously tested for PD-L1 expression and should have PD-L1 expression ≥1 or \<1 by CPS or TPS based on historical testing
  • Part D and Part E:

    • Participants must have histologically or cytologically-confirmed disease of the HNSCC or NSCLC
    • Participants must have PD-L1 expression based on historical testing
    • Participants with NSCLC; PD-L1 expression ≥ 1% by TPS
    • Participants with HNSCC; PD--L1 expression ≥1 by CPS
  • (ECOG) performance status score of 0 or 1
  • per v1.1 at baseline

Exclusion criteria

Exclusion Criteria:

  • History of another within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy.
  • Known active central nervous system . Participants with previously-treated may participate provided they:

    • Are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment
    • Have no new or enlarging brain metastases
    • And are off of prescribed for symptoms associate with brain metastases for at least 7 days prior to first dose of study treatment
  • Lepto-meningeal disease
  • Prior treatment with an agent within less than 5 half-lives. This duration of time will vary according to the half-life of the specific agent.
  • Previous receipt of an monomethylauristatin E (MMAE)-containing agent.
  • Pre-existing neuropathy ≥Grade 2 per National Cancer Institute (NCI CTCAE) v5.0.

There are additional inclusion criteria. The study center will determine if criteria for participations are met.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
714 participants (estimated)

Study arms

  • Experimental
    PF-08046054 Monotherapy

    PF-08046054 monotherapy

    Drug: PF-08046054

  • Experimental
    PF-08046054 Combination Therapy

    PF-08046054 + pembrolizumab

    Drug: PF-08046054 · Drug: pembrolizumab

Interventions

  • DrugPF-08046054

    Given into the vein (IV; intravenously)

    Also known as: SGN-PDL1V

  • 200 mg once every 3 weeks given into the vein (IV; intravenously)

    Also known as: Keytruda

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Through approximately 90 days after last study treatment; up to 3 years

  2. Number of participants with laboratory abnormalities

    Time frame: Through approximately 90 days after last study treatment; up to 3 years

  3. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Through the first cycle of study treatment; approximately 1 month

  4. Number of participants with DLTs by dose level

    Time frame: Through the first cycle of study treatment; approximately 1 month

Secondary outcomes

  1. Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by investigator assessment

    The proportion of participants with a partial response (PR) or complete response (CR) which is subsequently confirmed per RECIST v1.1 as assessed by the investigator.

    Time frame: Up to approximately 3 years

  2. Duration of objective response (DOR) per RECIST v1.1 by investigator assessment

    The time from the start of the first documentation of objective tumor response (CR or PR that is subsequently confirmed) to the first documentation of PD (per RECIST v1.1 as assessed by the investigator) or to death due to any cause.

    Time frame: Up to approximately 3 years

  3. Progression-free survival (PFS) per RECIST v1.1 by investigator assessment

    The time from the start of study treatment to the first documentation of PD (per RECIST v1.1 as assessed by the investigator) or death due to any cause.

    Time frame: Up to approximately 3 years

  4. Overall survival (OS)

    The time from the start of study treatment to death due to any cause.

    Time frame: Up to approximately 3 years

  5. Pharmacokinetic (PK) parameter - Area under the concentration-time curve (AUC)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment; up to approximately 3 years

  6. PK parameter - Maximum concentration (Cmax)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment; up to approximately 3 years

  7. PK parameter - Trough concentration (Ctrough)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment; up to approximately 3 years

  8. Incidence of anti-drug antibodies (ADAs)

    To be summarized using descriptive statistics

    Time frame: Through 30-37 days after last study treatment; up to approximately 3 years

07

Study locations

62 of 62 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jan 2028, 62 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 62 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 26, 2022
StartActual
Oct 25, 2022
Primary completionEst.
Jan 5, 2028
CompletionEst.
Jan 4, 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05208762
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
Oct 25, 2022
Primary completion
Jan 5, 2028 (estimated)
Completion
Jan 4, 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Seagen Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion